Insider plans 4,750-share Zevra Therapeutics (ZVRA) Rule 144 sale on NASDAQ

Rhea-AI Filing Summary

Zevra Therapeutics (symbol ZVRA) has a planned insider sale of shares under Rule 144. A holder intends to sell 4,750 shares of the company’s common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 42085.00 as of the notice.

The shares were acquired as restricted stock units from the issuer on 01/30/2026, with the same date shown for acquisition and payment. The notice includes the required representation that the seller is not aware of any undisclosed material adverse information about Zevra’s current or prospective operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4750	42085.00	56297535	01/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/30/2026	Restricted Stock Units	Issuer			4750	01/30/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for ZVRA disclose?

The Form 144 discloses a planned sale of 4,750 shares of ZVRA common stock. The shares are to be sold under Rule 144 on NASDAQ, with an aggregate market value of 42085.00 and were acquired as restricted stock units from the issuer.

How many ZVRA shares are planned to be sold and at what value?

The filing shows a planned sale of 4,750 ZVRA common shares with an aggregate market value of 42085.00. This amount reflects the market value associated with the notice and is routed through Morgan Stanley Smith Barney LLC on NASDAQ.

How were the ZVRA shares in this Form 144 acquired?

The 4,750 ZVRA shares were acquired as restricted stock units from the issuer. Both the acquisition date and the payment date are listed as 01/30/2026, and the nature of payment is indicated as N/A in the disclosure table.

Which broker will handle the ZVRA Form 144 share sale?

The planned ZVRA share sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The broker’s address is listed as 1 New York Plaza, 8th Floor, New York, NY 10004, and the shares are to be sold on NASDAQ.

What does the Rule 144 representation mean in the ZVRA filing?

The person for whose account the ZVRA shares are to be sold represents that they do not know of any undisclosed material adverse information about the issuer. This representation is a standard requirement when filing a notice of proposed sale under Rule 144.

How many ZVRA shares are shown as outstanding in the Form 144?

The filing lists 56,297,535 ZVRA common shares as outstanding. This figure is presented as a baseline reference for the issuer’s capital structure and is separate from the 4,750 shares covered by the planned Rule 144 sale.